Source: http://www.google.com/patents/US8158118?dq=U.S.+Patent+No.+4,528,643)
Timestamp: 2016-07-26 01:11:15
Document Index: 373807060

Matched Legal Cases: ['Art. 94', 'Application No. 05787106', 'Art. 94', 'Application No. 05787106', 'Application No. 04723937', 'Application No. 05754008', 'Application No. 05787106', 'Application No. 2006', 'Application No. 05754008']

Patent US8158118 - Mesenchymal precursor cell - Google PatentsSearch Images Maps Play YouTube News Gmail Drive More »Sign inPatentsA method of enriching mesenchymal precursor sells including the step of enriching for cells based on at least two markers. The markers may be either i) the presence of markers specific for mesenchymal precursor cells, ii) the absence of markers specific for differentiated mesenchymal cells, or iii) expression...http://www.google.com/patents/US8158118?utm_source=gb-gplus-sharePatent US8158118 - Mesenchymal precursor cellAdvanced Patent SearchPublication numberUS8158118 B2Publication typeGrantApplication numberUS 11/169,875Publication dateApr 17, 2012Priority dateJul 7, 1999Fee statusPaidAlso published asUS7122178, US7399632, US20050281790, US20060008452, WO2001004268A1Publication number11169875, 169875, US 8158118 B2, US 8158118B2, US-B2-8158118, US8158118 B2, US8158118B2InventorsPaul Simmons, Andrew Zannettino, Stan GronthosOriginal AssigneeAngioblast Systems, Inc.Export CitationBiBTeX, EndNote, RefManPatent Citations (37), Non-Patent Citations (132), Referenced by (6), Classifications (14), Legal Events (3) External Links: USPTO, USPTO Assignment, EspacenetMesenchymal precursor cell
An exogenous nucleic acid that encodes a protein or peptide with therapeutic may be transformed into the enriched population using standard techniques. (see U.S. Pat. No. 5,591,625 by Gerson et al.). The transformed cell population can then be introduced into the body of the patient to treat a disease or condition. For example, can be used to provide a continuous delivery of insulin, or genes encoding Factor VIII which is involved in clotting and therefore may be used in haemophiliacs.
Patent CitationsCited PatentFiling datePublication dateApplicantTitleUS5197985Nov 16, 1990Mar 30, 1993Caplan Arnold IMethod for enhancing the implantation and differentiation of marrow-derived mesenchymal cellsUS5226914Nov 16, 1990Jul 13, 1993Caplan Arnold IMethod for treating connective tissue disordersUS5405772Jun 18, 1993Apr 11, 1995Amgen Inc.Medium for long-term proliferation and development of cellsUS5486359Feb 8, 1994Jan 23, 1996Osiris Therapeutics, Inc.Human mesenchymal stem cellsUS5580754Aug 23, 1994Dec 3, 1996Amgen Inc.Nucleic acid encoding the progenitor B cell stimulating factorUS5591625Nov 24, 1993Jan 7, 1997Case Western Reserve UniversityTransduced mesenchymal stem cellsUS5811094Apr 11, 1995Sep 22, 1998Osiris Therapeutics, Inc.Connective tissue regeneration using human mesenchymal stem cell preparationsUS5827740Jul 30, 1996Oct 27, 1998Osiris Therapeutics, Inc.Adipogenic differentiation of human mesenchymal stem cellsUS5837539Jun 2, 1995Nov 17, 1998Osiris Therapeutics, Inc.Monoclonal antibodies for human mesenchymal stem cellsUS5922597Nov 13, 1996Jul 13, 1999Regents Of The University Of MinnesotaEx vivo culture of stem cellsUS5980887Nov 8, 1996Nov 9, 1999St. Elizabeth's Medical Center Of BostonMethods for enhancing angiogenesis with endothelial progenitor cellsUS6022540Aug 28, 1998Feb 8, 2000Osiris Therapeutics, Inc.Ligands that modulate differentiation of mesenchymal stem cellsUS6087113May 19, 1998Jul 11, 2000Case Western Reserve UniversityMonoclonal antibodies for human mesenchymal stem cellsUS6261549Jul 1, 1998Jul 17, 2001Osiris Therapeutics, Inc.Human mesenchymal stem cells from peripheral bloodUS6322784Oct 26, 1998Nov 27, 2001Osiris Therapeutics, Inc.Adipogenic differentiation of human mesenchymal stem cellsUS6335195Jan 23, 1998Jan 1, 2002Maret CorporationMethod for promoting hematopoietic and mesenchymal cell proliferation and differentiationUS6387367May 28, 1999May 14, 2002Osiris Therapeutics, Inc.Human mesenchymal stem cellsUS6387369Jul 14, 1998May 14, 2002Osiris Therapeutics, Inc.Cardiac muscle regeneration using mesenchymal stem cellsUS6645727May 25, 2001Nov 11, 2003Stemcell Technologies Inc.Antibody compositions for preparing enriched mesenchymal progenitor preparationsUS6709864Mar 28, 2000Mar 23, 2004Osiris Therapeutics, Inc.Adipogenic differentiation of human mesenchymal stem cellsUS7122178 *Jul 7, 2000Oct 17, 2006Angioblast Systems, IncorporatedMesenchymal precursor cellUS20020085996Nov 13, 2001Jul 4, 2002Mcintosh Kevin R.Mesenchymal stem cells for prevention and treatment of immune responses in transplantationUS20040107453Feb 14, 2002Jun 3, 2004Furcht Leo TMultipotent adult stem cells, sources thereof, methods of obtaining same, methods of differentiation thereof, methods of use thereof and cells derived thereofUS20050019911Mar 29, 2004Jan 27, 2005Medvet Science Pty LtdMesenchymal precursor cellUS20050158289Sep 29, 2004Jul 21, 2005Simmons Paul J.Mesenchymal precursor cell and use thereof in the repair of bone defects and fractures in mammalsUS20060008452Jul 11, 2005Jan 12, 2006Medvet Science Pty Ltd.Mesenchymal precursor cellUS20060193840Jan 5, 2006Aug 31, 2006Stan GronthosPerivascular mesenchymal precursor cell induced blood vessel formationUS20060286077Mar 29, 2004Dec 21, 2006Stan GronthosPerivascular mesenchymal precursor cell induced blood vessel formationUS20070065938Mar 29, 2004Mar 22, 2007Stan GronthosPerivascular mesenchymal precursor cellsUS20070274958Apr 19, 2003Nov 29, 2007Songtao ShiPostnatal Stem Cells and Uses ThereofWO1999003973A1Jul 14, 1998Jan 28, 1999Osiris Therapeutics, Inc.Cardiac muscle regeneration using mesenchymal stem cellsWO2000006701A1Jul 29, 1999Feb 10, 2000Genzyme CorporationImprovement of cardiac function by mesenchymal stem cell transplantationWO2001004268A1Jul 7, 2000Jan 18, 2001Medvet Science Pty LtdMesenchymal precursor cellWO2001011011A2Aug 4, 2000Feb 15, 2001Mcl LlcMultipotent adult stem cells and methods for isolationWO2002007679A2Jul 23, 2001Jan 31, 2002The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human ServicesAdult human dental pulp stem cells in vitro and in vivoWO2004084921A1Mar 29, 2004Oct 7, 2004Angioblast Systems IncorporatedPerivascular mesenchymal precursor cell induced blood vessel formationWO2004085630A1Mar 29, 2004Oct 7, 2004Angioblast Systems IncorporatedPerivascular mesenchymal precursor cells* Cited by examinerNon-Patent CitationsReference1Alberico et al (1987) Blood;69:1120.2Al-khaldi et al. (2003) "Therapeutic Angiogenesis Using Autologous Bone Marrow Stromal Cells: Improved Blood Flow in a Chronic Limb Ischemia Model" Ann Thorac Surg 75:204-209.3Allen et al (1990a) Immunol. Ser. 49:1.4Allen et al (1990b) Marrow Biology and Stem Cells. In Colony Stimulating Factors: Molecular and Cellular Biology, edited by T.M. Dexter, J.M. Garland and N.G. Testa: New York: Marcel Decker, 1990b. pp. 1-38.5Allen, T.D.: Haemopoietic microenvironment in vitro: Ultrastructural aspects. In Porter R. Whelan J (eds); "Microenvironments in haemopoietic and lymphoid differentiation." CIBA Foundation Symposium 84. London: Pitman Medical, 1981, pp. 38-67.6Anklesaria et al (1987) Proc. Natl. Acad. Sci. USA. 84:7681.7Anklesaria et al (1989) Blood. 74:1144.8Apr. 28, 2009 Final Office Action issued in connection with U.S. Appl. No. 10/813,747.9Apr. 4, 2008 Restriction Requirement issued in connection with U.S. Appl. No. 10/551,326.10Axelrad et al., New Technologies for the Enhancement of Skeletal Repair, Injury, Int. J. Care Injured (2007) 38S1:S49-S62.11Barry, F.P. (2003) "Biology and Clinical Applications of Mesenchymal Stem Cells." Birth Defect Research (Part C) 69:250-256.12Bennett et al (1991) Journal of Cell Science. 99:131.13Bentley (1982) Br J Haematol. 50:1.14Bianco, P. et al. (2001), "Bone Marrow Stromal Stem Cells: Nature, Biology, and Potential Applications," Stem Cells 19:180-192.15Bruder et al., Mesenchymal Stem Cells in Bone Development, Bone Repair, and Skeletal Regeneration Therapy, J. Cell Biochem; (1994) 56:283-294.16Cassiede, P. et al. (1996) "Osteochondrogenic Potential of Marrow Mesenchymal Progenitor Cells Exposed to . . . " Journal of Bone and Mineral Research vol. 11(9):1264-1273.17Castro-Malaspina et al (1980) Blood. 56:289.18Castro-Malaspina et al. (1981) Blood. 57:781.19Chopp, M. and Li, Y. (2002) "Treatment of Neural Injury with Marrow Stromal Cells." The Lancet Neurology 1:92-100.20Clarke, Emer, "Mesenchymal Cells" www.stemcell.com (mini-review).21Cochlovius, B. et al. (2003) "Therapeutic Antibodies," Modern Drug Discovery pp. 33-34, 37-38.22Communication Pursuant to Art. 94(3) EPC issued Apr. 16, 2010 in connection with European Application No. 05787106.3.23Communication Pursuant to Art. 94(3) EPC issued Dec. 16, 2010 in connection with European Application No. 05787106.3.24Dennis et al., Osteogenesis in Marrow-Derived Mesenchymal Cell Porous Ceramic Composites Transplanted Subcutaneously: Effect of Fibronectin and Laminin on Cell Retention and Rate of Osteogenic Expression, Cell Transplant (1992) 1:23-32, Abstract.25Dennis JE, et al. (2002), The STRO-1+ Marrow Cell Population is Multipotential, Cells Tissues Organs, 170:73-82.26Dexter et al Kroc Foundation Series vol. 18; Alan R. Liss, Inc., New York; p. 57-96. 1984.27Dexter et al. (1977) J Cell Physiol. 91:335.28Doherty, M.J. et al. (1998) "Vascular Pericytes Express Osteogenic Potential In Vitro and In Vitro" J. Bone and Mineral Research 13, pp. 828-838.29European Examination Report issued Feb. 27, 2009 in connection with European Application No. 04723937.1.30Examination report issued Oct. 10, 2009 in connection with European Application No. 05754008.0.31Extended European Search Report issued Dec. 27, 2007 in connection with European Application No. 05787106.3.32Final Office Action issued Jul. 16, 2009 in connection with U.S. Appl. No. 10/955,709.33Final Office Action issued Jun. 22, 2009 in connection with U.S. Appl. No. 10/551,162.34Final Office Action issued Oct. 8, 2009 in connection with U.S. Appl. No. 11/326,736.35Final Office Action issued Sep. 29, 2009 in connection with U.S. Appl. No. 10/551,326.36Finney, M.R. et al. (2006) Direct Comparison of Umbilical Cord Blood versus Bone Marrow-Derived Endothelial Precursor Cells in . . . Biol. Blood and Marrow Transplant 12:585-593.37Fong et al (1997) BioTechniques. 23:1029.38Friedenstein (1976) International Review of Cytology. 47:327.39Friedenstein (1980) "Stromal mechanisms of bone marrow: cloning in vitro and retransplantation in vivo." Immunology of Bone Marrow Transplantation; Ed: S. Thienfelder; Springer-Verlag Berlin; p. 19-29, 1980.40Friedenstein et al (1970) Cell Tissue Kinetics. 3:393.41Friedenstein et al. (1992) Bone and Mineral. 18:199.42Fujii, S. et al. (2008), "Investigating a Clonal Human Periodontal Ligament Progenitor/Stem Cell Line In Vitro and In Vivo," J. Cell. Physiol. 215:743-749.43Greenberger, J. and Keating, A. (1996) "The Hematopoietic Effects Microenvironment." Keystone Symposium, Taos, New Mexico14:366-367.44Gronthos and Simmons (1995) Blood. 85:929.45Gronthos et al. (1994) Blood. 84:4164.46Gronthos et al. Journal of Hematotherapy, 1996. 5, 15-23.47Gronthos S et al: "Postnatal human dental pulp stem cells (DPSCs) in vitro and in vivo." Proceedings of the National Academy of Sciences of USA, National Academy of Science, Washington, DC, US, vol. 97, No. 25, Dec. 5, 2000, pp. 13625-13630.48Gronthos, S. et al. (2002) "Stem Cell Properties of Human Dental Pulp Stem Cells" J. Dent. Res. 81(8), pp. 531-535.49Gronthos, S., et al., "The STRO-1+ Fraction of Adult Human Bone Marrow Contains the Osteogenic Precursors," Blood, vol. 84, No. 12, 1994, pp. 4164-4173.50Gronthos, S., et al., (1999) "Differential Cell Surface Expression of the STRO-1 and Alkaline Phosphatase Antigens on Discrete Developmental Stages in Primary Culture of Human Bone Cells," Journal of Bone and Mineral Research, 14(1): 47-56.51Hansson, M. et al. (2007) "Commentary: Isolated Stem Cells-Patentable as Cultural Artifacts?" V.25, pp. 1507-1510.52Hellstrom et al. (1999) Development 126, 2047.53Hoerstrup SP et al. (2002), Tissue Engineering of Functional Trileaflet Heart Valves From Human Marrow Stromal Cells, Circulation 106(Suppl):I-143-I150.54Holden et al. (2002), "Plasticity Time for A Reappraisal?" Science 296:2126-2129.55Huang and Terstappen (1992) Nature. 360:745.56International Preliminary Report . . . issued by the International Bureau of WIPO on Oct. 1, 2005 in connection with International Application No. PCT/AU2004/000416.57International Preliminary Report on Patentability issued by the International Bureau of WIPO on Oct. 1, 2005 in connection with International Application No. PCT/AU2004/000417.58International Preliminary Report on Patentability issued May 17, 2004 in connection with International Application No. PCT/AU2004/000416.59International Search Report issued by the International Searching Authority (ISA/AU) on Aug. 22, 2005 in connection with International Application No. PCT/AU2005/000953.60International Search Report issued by the International Searching Authority (ISA/AU) on May 17, 2004 in connection with International Application No. PCT/AU2004/000416.61International Search Report issued by the International Searching Authority (ISA/AU) on May 17, 2004 in connection with International Application No. PCT/AU2004/000417.62International Search Report issued by the International Searching Authority (ISA/AU) on Nov. 25, 2005 in connection with International Application No. PCT/AU2005/001445.63Ji, et al., (2004) "Interactions of Chemokines and Chemokine Receptors Mediate the Migration of Mesenchymal Stem Cells to the Impaired Site in the Brain After Hypoglossal Nerve Injury," Stem Cells, 22: 415-427.64Jones, E.A. et al. (2002) "Isolation and Characterization of Bone Marrow Multipotential Mesenchymal Progenitor Cells" Arthritis & Rheumatism 46(12), pp. 3349-3360.65Kanbe K. et al. (2002) "Stimulation of Matrix Matalloprotease 3 Release from Human Chondrocytes by the Interaction of Stromal Cell-Derived . . . "Arthritis & Rheumatism 46:130-137.66Kang Yong Jung et al. (2004) "Involvement of PI-3-kinase, JNK, PKC, and PKA in the PDGF-induced proliferation in human adipose tissue-derived . . . " vol. 18(8) C253.67Kassem, M. (2004) "Mesenchymal Stem Cells: Biological Characteristics and Potential Clinical Applications." Cloning Stem Cells 6:369-374.68Keating et al. (1982) Nature. 298: 280.69Kim et al. (1994) Science, 266:2011.70Knopse et al. (1966) Blood. 28:398.71Knopse et al. (1972) Blood. 39:331.72Kocher et al. (2001) "Neovascularization of Ischemic Myocardium by Human Bone-Marrow-Derived Angioblasts Prevents Cardiomyocyte Apoptosis, Reduces Remodeling and Improves Cardiac Function" Nature Medicine 7:430-436.73Kortesidis, et al., (2005) "Stromal-derived factor-1 promotes the growth, survival, and development of human bone marrow stromal stem cells," Blood, 105(10): 3793-3801.74Le Blanc, K. and Ringden, O. (2005) "Immunobiology of Human Mesenchymal Stem Cells and Future Use in Hematopoietic . . . " Biology of Blood and Marrow Transplantation 11:321-334.75Lichtman (1981) Experimental Hematology. 9:391.76Long (1992) Exp Hematol. 20:288.77MacManus and Weiss (1984) Blood. 64:1036.78McIntyre and Bjornson (1986) Exp Hematol. 14:833.79Miltenyi et al. (1990) Cytometry. 11:231.80Murray et al. (1996) "Fetal Bone Marrow CD34+CD41+ Cells are Enriched for Multipotent Hematopoietic Progenitors, but not for Pluripotent Stem Cells." Exp. Hematol. 24:236-245.81Neuhaus T. et al. (2003) "Stromal cell-derived factor 1alpha (SDF-1alpha) induces gene-expression of early growth response-1 . . . " Cell Proliferation. 36:75-86.82Notice of Allowance issue Jan. 14, 2011 in connection with U.S. Appl. No. 10/551,162.83Nov. 13, 2008 Office Action issued in connection with U.S. Appl. No. 10/551,326.84Nov. 17, 2008 Office Action issued in connection with U.S. Appl. No. 11/326,736.85Oct. 16, 2008 Office Action issued in connection with U.S. Appl. No. 10/955,709.86Oct. 29, 2009 Notice of Allowance issued in connection with U.S. Appl. No. 10/813,747.87Office Action Issued Aug. 26, 2010 in connection with U.S. Appl. No. 10/551,162.88Office Action issued Jan. 19, 2010 in connection with corresponding Japanese Application No. 2006-503989.89Office Action issued Jan. 19, 2011 in connection with U.S. Appl. No. 10/551,326.90Office Action issued Jan. 24, 2011 in connection with U.S. Appl. No. 12/660,003.91Office Action issued Mar. 16 2010 in connection with U.S. Appl. No. 11/663,570.92Office Action issued May 24, 2011 in connection with U.S. Appl. No. 11/326,736.93Office Action issued Nov. 8, 2010 in connection with U.S. Appl. No. 12/660,003.94Office Action issued Sep. 22, 2009 in connection with U.S. Appl. No. 11/663,570.95Owen (1985) Bone and Mineral Research. 3:1.96Owen and Friedenstein (1988) CIBA Foundation symposium. 136:42.97Pan, Beiqing et al. (2004) "The nitrogen-containing bisphosphonate, zaledronic acid, increases mineralisation of human bone-derived cells in vitro." Bone 34:112-123.98Perkins and Fleischman (1990) Blood. 75:620.99Piersma et al. (1983) Br. J. Haematol. 54:285.100Poulsom et al. (2003), "Bone Marrow Stem Cells Contribute to Healing of the Kidney," J. Am. Soc. Nephrol. 14:s48-s54.101Reyes et al. (2002) "Origin of Endothelial Progenitors in Human Postnatal Bone Marrow" Clin. Invest. 109:337-346.102Rothstein et al. (1985) Blood. 65:744.103Salcedo R. et al. (1999) "Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 . . . " American Journal of Pathology. 154:1125-1135.104Sep. 12, 2008 Office Action issued in connection with U.S. Appl. No. 10/551,162.105Shi S et al: "Perivascular niche of postnatal mesenchymal stem cells in human bone marrow and dental pulp." Journal of Bone and Mineral Research, New York, NY, US, vol. 18, No. 4, Apr. 2003, p. 696-704.106Shi S et al: "Perivascular niche of postnatal mesenchymal stem cells in human bone marrow and dental pulp." Journal of Bone and Mineral Research, vol. 17, No. Suppl 1, Sep. 2002, p. S446, XP009083412 & Twenty-Fourth Annual meeting of the American Society for Bone and Mineral Research; San Antonio, Texas, USA; Sep. 20-24, 2002.107Shi, S. et al. (2001) "Comparison of Human Dental Pulp and Bone Marrow Stromal Stem Cells by cDNA Microarray Analysis" Bone 29(6), pp. 532-539.108Simmons and Gronthos. (1991) International Journal of Cell Cloning. 9:408 [abstract].109Simmons and Torok-Storb (1991a) Blood. 78:55.110Simmons and Torok-Storb (1991b) Blood. 78:2848.111Simmons et al. (1987) Nature 328:429.112Simmons et al.(1994) Advances in Bone Marrow Purging and Processing: Fourth International Symposium. Progress in Clinical Biological Research. 389:271.113Simmons, P.J., et al., "Isolation, Characterization and Functional Activity of Human Marrow Stromal Progenitors in Hemopoiesis," Advances in Bone Marrow Purging and Processing: Fourth International Symposium, 1994, pp. 271-280.114Sordi, et al., (2005) "Bone marrow mesenchymal stem cells express a restricted set of functionally active chemokine receptors capable of promoting migration to pancreatic islets," Blood, 106(2): 419-427.115Stewart, K., et al., (1999) "Further Characterization of Cells Expressing STRO-1 In Cultures of Adult Human Bone Marrow Stromal Cells," Journal of Bone and Mineral Research, 14(8): 1345-1356.116Summer, R. and Fine, A. (2008) "Mesenchymal Progenitor Limitations and Recommendations." Proc.Am, Thorac. Soc 5:707-710.117Supplementary European Search Report from European Patent Office, Application No. EP 04 72 3935, May 10, 2007.118Supplementary European Search Report from European Patent Office, Application No. EP 04 72 3937, May 25, 2007.119Supplementary European Search Report issued Jan. 2, 2008 in connection with European Application No. 05754008.0.120Tavassoli and Crosby (1968) Science. 161:54.121Tavassoli and Friedenstein (1983) Ann J Hematol. 15:195.122Testa et al. (1988) Long-term Bone Marrow Damage after Cytotoxic Treatment:Stem Cells and Microenvironment in Hematopoiesis: Long-term Effects of Chemotherapy and Radiation (Hematology/vol. 8), eds. Testa, N.G., Gale, R.P., Marcel Dekker, Inc. New York and Basel, 1988, pp. 75-92.123Tse H F et al: "Angiogenesis in ischaemic myocardium by intramyocardial autologous bone marrow mononuclear cell implantation." Lancet The, Lancet Limited, London, GB, vol. 361, No. 9351, Jan. 4, 2003, pp. 47-49.124U.S. Appl. No. 11/663,563, filed Mar. 23, 2007.125U.S. Appl. No. 11/663,570, filed Mar. 23, 2007.126Van Vlasselaer et al (1994) Blood. 84:753.127Waller et al. (1995) Blood. 85:2422.128Weiss (1976) Anatomical Record. 186:161.129Wynn, et al., (2004) "A small proportion of mesenchymal stem cells strongly expresses functionally active CXCR4 receptor capable of promoting migration to bone marrow," Blood, 104(9): 2643-2645.130Yang XV, et al. (2006), "Evaluation of Human Bone Marrow Stromal Cell Growth on Biodegradable . . . " Biochemical and Biophysical Research Communications 342:1098-1107.131Zoltowska, et al. (2001) Arch Immunol Ther Exp (Warsz) 49:59-61.132Zvaifler, et al., (2000) "Mesenchymal precursor cells in the blood of normal individuals," Arthritis Research and Therapy, 2: 477-488.Referenced byCiting PatentFiling datePublication dateApplicantTitleUS9169466Mar 29, 2004Oct 27, 2015Mesoblast, Inc.Perivascular mesenchymal precursor cell induced blood vessel formationUS9175267Jan 5, 2006Nov 3, 2015Mesoblast, Inc.Perivascular mesenchymal precursor cell induced blood vessel formationUS20060193840 *Jan 5, 2006Aug 31, 2006Stan GronthosPerivascular mesenchymal precursor cell induced blood vessel formationUS20060286077 *Mar 29, 2004Dec 21, 2006Stan GronthosPerivascular mesenchymal precursor cell induced blood vessel formationUS20100098671 *Jun 7, 2007Apr 22, 2010Modern Cell & Tissue Technologies Inc.composition for prevention or treatment of bone marrow damageUS20110223668 *Sep 16, 2010Sep 15, 2011Angioblast Systems, Inc.Method of enhancing proliferation and/or survival of mesenchymal precursor cells (MPC)* Cited by examinerClassifications U.S. Classification424/93.1, 435/325, 424/577, 435/372International ClassificationA61K35/12, A61K35/26, C12N5/00, C12N5/0775, A01N63/00Cooperative ClassificationC12N2501/39, C12N2500/42, A61K2035/124, C12N5/0663European ClassificationC12N5/06B21PLegal EventsDateCodeEventDescriptionMar 13, 2006ASAssignmentOwner name: ANGIOBLAST SYSTEMS, INCORPORATED, NEW YORKFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MEDVET SCIENCES PTY LTD;REEL/FRAME:017679/0427Effective date: 20041004Owner name: ANGIOBLAST SYSTEMS, INCORPORATED,NEW YORKFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MEDVET SCIENCES PTY LTD;REEL/FRAME:017679/0427Effective date: 20041004May 10, 2012ASAssignmentOwner name: MESOBLAST, INC., NEW YORKFree format text: CHANGE OF NAME;ASSIGNOR:ANGIOBLAST SYSTEMS, INC.;REEL/FRAME:028192/0789Effective date: 20110930Sep 30, 2015FPAYFee paymentYear of fee payment: 4RotateOriginal ImageGoogle Home - Sitemap - USPTO Bulk Downloads - Privacy Policy - Terms of Service - About Google Patents - Send FeedbackData provided by IFI CLAIMS Patent Services